{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:10:10Z","timestamp":1784549410039,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.urolonc.2025.12.010","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:54:06Z","timestamp":1768708446000},"page":"110974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["High AST and the presence of liver metastases may guide for the need for FDG PET in advanced prostate cancer patients"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9939-282X","authenticated-orcid":false,"given":"Tugce","family":"Telli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Tuncel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdem","family":"Karabulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Erman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Akdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem","family":"Caglar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.urolonc.2025.12.010_bib0001","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2967\/jnumed.112.114116","article-title":"Baseline 18F-FDG PET\/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer","volume":"54","author":"Jadvar","year":"2013","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.urolonc.2025.12.010_bib0002","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamaoncol.2017.3588","article-title":"Positron emission tomography\/computed tomography-based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer","volume":"4","author":"Fox","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2025.12.010_bib0003","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.010_bib0004","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol,"},{"key":"10.1016\/j.urolonc.2025.12.010_bib0005","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fonc.2017.00131","article-title":"The metabolic phenotype of prostate cancer","volume":"7","author":"Eidelman","year":"2017","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.12.010_bib0006","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41391-020-0202-x","article-title":"GLUT1 expression in high-risk prostate cancer: correlation with (18)F-FDG-PET\/CT and clinical outcome","volume":"23","author":"Meziou","year":"2020","journal-title":"Prostate Cancer Prostat Dis"},{"issue":"11","key":"10.1016\/j.urolonc.2025.12.010_bib0007","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/pros.22831","article-title":"Utility of FDG-PET in clinical neuroendocrine prostate cancer","volume":"74","author":"Spratt","year":"2014","journal-title":"The Prostate"},{"issue":"6","key":"10.1016\/j.urolonc.2025.12.010_bib0008","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.010_bib0009","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13550-020-00640-2","article-title":"Neuron-specific enolase has potential value as a biomarker for [(18)F]FDG\/[(68)Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients","volume":"10","author":"Rosar","year":"2020","journal-title":"EJNMMI Res"},{"issue":"6","key":"10.1016\/j.urolonc.2025.12.010_bib0010","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s00259-020-05160-8","article-title":"Prognostic implications of dual tracer PET\/CT: PSMA ligand and [(18)F]FDG PET\/CT in patients undergoing [(177)Lu]PSMA radioligand therapy","volume":"48","author":"Michalski","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.010_bib0011","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","article-title":"Current methods to define metabolic tumor volume in positron emission tomography: which one is better?","volume":"52","author":"Im","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.010_bib0012","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41391-019-0174-x","article-title":"Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies","volume":"23","author":"Iravani","year":"2020","journal-title":"Prostat Cancer Prostat Dis"},{"issue":"4","key":"10.1016\/j.urolonc.2025.12.010_bib0013","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1464-410X.2006.06663.x","article-title":"Liver metastases in prostate carcinoma: clinical characteristics and outcome","volume":"99","author":"Pouessel","year":"2007","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.urolonc.2025.12.010_bib0014","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/hep.28755","article-title":"Liver protects metastatic prostate cancer from induced death by activating E-cadherin signaling","volume":"64","author":"Ma","year":"2016","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"5930","key":"10.1016\/j.urolonc.2025.12.010_bib0015","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"science"},{"issue":"3","key":"10.1016\/j.urolonc.2025.12.010_bib0016","first-page":"117","article-title":"The de ritis ratio: the test of time","volume":"34","author":"Botros","year":"2013","journal-title":"Clin Biochem Rev"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.010_bib0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.juro.2015.01.083","article-title":"The preoperative AST\/ALT (De Ritis) ratio represents a poor prognostic factor in a cohort of patients with nonmetastatic renal cell carcinoma","volume":"194","author":"Bezan","year":"2015","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.12.010_bib0018","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.21873\/anticanres.12711","article-title":"Significance of de ritis (Aspartate Transaminase\/Alanine Transaminase) ratio as a significant prognostic but not predictive biomarker in Japanese patients with metastatic castration-resistant prostate cancer treated with Cabazitaxel","volume":"38","author":"Miyake","year":"2018","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.urolonc.2025.12.010_bib0019","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2214\/AJR.17.18112","article-title":"Metabolic PET imaging in oncology","volume":"209","author":"Sai","year":"2017","journal-title":"Am J Roentgenol"},{"issue":"20","key":"10.1016\/j.urolonc.2025.12.010_bib0020","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.3390\/cancers15204907","article-title":"Prognostic value of the de ritis ratio for overall survival in patients with metastatic castration-resistant prostate cancer undergoing [177Lu] Lu-PSMA-617 radioligand therapy","volume":"15","author":"Gaal","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.010_bib0021","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2967\/jnumed.120.262250","article-title":"The added value of 18F-FDG PET\/CT compared with 68Ga-PSMA PET\/CT in patients with castration-resistant prostate cancer","volume":"63","author":"Chen","year":"2022","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.urolonc.2025.12.010_bib0022","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.2967\/jnumed.114.145490","article-title":"Relationship between [18F]F-FDG accumulation and lactate dehydrogenase A expression in lung adenocarcinomas","volume":"55","author":"Zhou","year":"2014","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.urolonc.2025.12.010_bib0023","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/MNM.0000000000000840","article-title":"Lactate dehydrogenase levels and 18F-FDG PET\/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma","volume":"39","author":"Alkhawtani","year":"2018","journal-title":"Nucl Med Commun"},{"issue":"11","key":"10.1016\/j.urolonc.2025.12.010_bib0024","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/iub.1216","article-title":"Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapy","volume":"65","author":"Miao","year":"2013","journal-title":"IUBMB Life"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:51:19Z","timestamp":1784548279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925004934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1078143925004934"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High AST and the presence of liver metastases may guide for the need for FDG PET in advanced prostate cancer patients","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110974"}}